ELOVL5

Across TCGA pan-cancer cohorts, ELOVL5 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ELOVL5 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ELOVL5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ELOVL5 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

LUAD, HNSC, and GBM are the cancer types where ELOVL5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.799	0.476	.006	16	view →
HNSC	DFS	Median	All	0.698	1.000	.020	6	view →
GBM	OS	Median	All	0.433	0.609	.017	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ELOVL5–LUAD (OS)

Open the LUAD breakdown →